|
Interagency Oncology Task Force Fellowship Opportunities
The Interagency Oncology Task Force (IOTF), a joint initiative between
The National Cancer Institute (NCI) and the
U.S. Food and Drug Administration
(FDA), announces this year’s fellowship training opportunities for Ph.D.s,
M.D.s, and M.D./Ph.D.s or their equivalents in cancer-related scientific
research and research-related regulatory review.
The IOTF Joint Fellowship Program trains a core of scientists in cancer
research and research-related regulatory review to develop skill sets
that bridge the two distinct processes. During the program, fellows will:
-
Build awareness of regulatory requirements into the early stages of medical product development
- Devise strategies to improve planning throughout the research and regulatory review phases
- Learn how to bring state-of-the art knowledge and technology to bear on the design, conduct, and review of clinical trials.
Fellowship programs are available for various career
levels and vary in length (1- 4 years). View each
program’s web page for more information:
Clinical Oncology Product Research/Review:
Application deadline: January 31, 2010
Earliest start date: July, 2010
Clinical Oncology Product Research/Review for Board Certified (BC) Oncologists:
Application deadline: January 31, 2010
Earliest start date: July, 2010
Oncology Product Research/Review:
Application deadline: May 30, 2010
Earliest start date: September, 2010
Cancer Prevention Fellows:
Application deadline: September 1, 2010
Earliest start date: July, 2011
The IOTF was established to
enhance and accelerate the overall
process of developing new cancer diagnostics
and therapeutics and speed their delivery to patients.
More information about the program fellowships can
be found at http://iotftraining.nci.nih.gov.
“We believe that physicians and scientists who are highly
trained in the regulatory process, and who also have an understanding
of the inner workings of NCI and FDA, will be able to facilitate
and speed the development and approval process for drugs, especially
for chemotherapy.”
- Dr. Jonathan Wiest, Director, NCI Center for Cancer Training
—posted 12/16/2009
|
